Delektorskaya V V, Chemeris G Yu, Zavalishina L E, Ryazantseva A A, Grigorchuk A Yu, Kononets P V, Davydov M I
N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences Russia.
Bull Exp Biol Med. 2010 Oct;149(5):615-20. doi: 10.1007/s10517-010-1007-z.
We performed a parallel evaluation of the status of epidermal growth factor receptors EGFR and HER-2 in tumor samples from 31 patients with squamous cell carcinoma of the esophagus. Hyperexpression of proteins was detected by immunohistochemical methods and gene amplification and other chromosome abnormalities were studied using FISH reaction. Evaluation of EGFR status showed that amplification of EGFR gene was present in 25% cases and chromosome 7 polysomy was detected in 29.2% cases positive by protein expression (2+/3+). Immunohistochemically positive EGFR status was confirmed by the results of FISH reaction for gene amplification and chromosome 7 polysomy in 54.2% cases (p=0.002). During evaluation of HER-2 status in the tumor, hyperexpression of the protein detected histochemically was not confirmed by FISH reaction for detection of amplification of the corresponding gene in 16.1% cases. In 22.6% patients, chromosome 7 polysomy was detected; it was not accompanied by amplification of HER-2 gene, but was related to immunohistochemically positive status of the tumor. Hyperexpression of EGFR protein significantly correlated with the presence of intravascular invasion (p=0.006) and increased depth of invasion (p=0.044), while amplification of EGFR gene (≥2.2) correlated with low differentiation degree of the tumor (p=0.006). The outcome of the disease was not associated with EGFR status at the gene and protein levels, whereas clinical course of the disease in patients with immunohistochemically negative expression of HER-2 protein was more favorable than in patients with positive expression (p=0.004). The results of this study suggest that hyperexpression/amplification of EGFR and hyperexpression of HER-2 are important clinical markers for evaluation of disease prognosis and development of new regimens of targeted therapy for patients with squamous cells carcinoma of the esophagus.
我们对31例食管鳞状细胞癌患者的肿瘤样本进行了表皮生长因子受体(EGFR)和HER-2状态的平行评估。采用免疫组化方法检测蛋白过表达,并使用荧光原位杂交(FISH)反应研究基因扩增及其他染色体异常情况。EGFR状态评估显示,25%的病例存在EGFR基因扩增,在蛋白表达阳性(2+/3+)的病例中,29.2%检测到7号染色体多体性。通过FISH反应检测基因扩增和7号染色体多体性的结果,在54.2%的病例中证实了免疫组化阳性的EGFR状态(p=0.002)。在评估肿瘤中的HER-2状态时,16.1%的病例通过FISH反应检测相应基因扩增,未证实组织化学检测到的蛋白过表达。在22.6%的患者中检测到7号染色体多体性;其未伴有HER-2基因扩增,但与肿瘤免疫组化阳性状态相关。EGFR蛋白过表达与血管内侵犯的存在显著相关(p=0.006),且与浸润深度增加相关(p=0.044),而EGFR基因扩增(≥2.2)与肿瘤低分化程度相关(p=0.006)。疾病结局与基因和蛋白水平的EGFR状态无关,而HER-2蛋白免疫组化阴性表达患者的疾病临床进程比阳性表达患者更有利(p=0.004)。本研究结果表明,EGFR的过表达/扩增和HER-2的过表达是评估食管鳞状细胞癌患者疾病预后及开发新的靶向治疗方案的重要临床标志物。